AURO-TELMISARTAN HCTZ TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

TELMISARTAN; HYDROCHLOROTHIAZIDE

Inapatikana kutoka:

AURO PHARMA INC

ATC kanuni:

C09DA07

INN (Jina la Kimataifa):

TELMISARTAN AND DIURETICS

Kipimo:

80MG; 12.5MG

Dawa fomu:

TABLET

Tungo:

TELMISARTAN 80MG; HYDROCHLOROTHIAZIDE 12.5MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

30/100/500/1000

Dawa ya aina:

Prescription

Eneo la matibabu:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0244783001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2016-07-18

Tabia za bidhaa

_Auro-Telmisartan HCTZ Product Monograph _Page 1 of 64
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AURO-TELMISARTAN HCTZ
Telmisartan and Hydrochlorothiazide Tablets, USP
Tablet, 80 mg/12.5 mg and 80 mg/25 mg, Oral
Angiotensin II AT
1
Receptor Blocker/ Diuretic
Auro Pharma Inc.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada
Date of initial Authorization:
July 18, 2016
Date of Revision:
January 26, 2023
Submission Control No: 267665
_Auro-Telmisartan HCTZ Product Monograph _Page 2 of 64
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
01 / 2023
7 WARNINGS AND PRECAUTIONS
01 / 2023
4 DOSAGE AND ADMINISTRATION
01 / 2023
TABLE OF CONTENTS
_Sections or subsections that are not applicable at the time of
authorization are not listed. _
RECENT MAJOR LABEL CHANGES
..............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1 INDICATIONS
........................................................................................................................
4
1.1 Pediatrics
............................................................................................................................................
4
1.2 Geriatrics
............................................................................................................................................
4
2 CONTRAINDICATIONS
...........................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
.......................................................................
5
4 DOSAGE AND ADMINISTRATION
...........................................................................................
5
4.1 Dosing Considerations
...................................................